Bioggio, Switzerland—The KD Pharma Group has acquired the manufacturing assets of a Swiss-based cannabinoid manufacturer, according to a press release.

These assets give KD Pharma access to technology that will allow them to produce Active Pharmaceutical Ingredients based on phytocannabinoids and other plant extracts, expanding KD’s lipid technology portfolio. The technology can also be used in combination with KD’s other fractionation and separation technologies.

Related: Stratum, KD Pharma Partner on Joint Health Ingredient Cannabis Medicine Association Launches for BIPOC Health Professionals CV Sciences, Alkemist Partner on Cannabis Testing Program

KD has also licensed a novel extraction method from Herbolea Biotech S.r.I. and expects to have a complete, licensed cGMP manufacturing facility online by the end of the year.

“KD Pharma is a leader in lipid technology focused primarily on omega-3s, but our technology suite has applications in other lipid sources like cannabinoids,” said Oscar Groet, CEO of the KD Pharma Group, in the press release. “We have committed to expanding our technology portfolio to develop APIs from cannabinoids and plant extracts,” Groet continued, “and these assets give KD Pharma additional pathways to develop new products for this emerging market.”